Biomarker Trial of Everolimus in Patients With Advanced Renal Cell Carcinoma

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborators:
Dana-Farber Cancer Institute
Duke University
Novartis
Information provided by (Responsible Party):
Daniel Cho, MD, Dana-Farber Cancer Institute
ClinicalTrials.gov Identifier:
NCT00827359
First received: January 21, 2009
Last updated: August 16, 2013
Last verified: August 2013

January 21, 2009
August 16, 2013
March 2009
January 2014   (final data collection date for primary outcome measure)
To prospectively validate the expression of phospho-Akt and phospho-S6 as predictive biomarkers of responsiveness to everolimus. [ Time Frame: 2 years ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT00827359 on ClinicalTrials.gov Archive Site
  • To estimate the progression-free survival in patients with advanced RCC treated with everolimus. [ Time Frame: 3 years ] [ Designated as safety issue: No ]
  • To determine the objective response rate to everolimus in patients with advanced RCC. [ Time Frame: 3 years ] [ Designated as safety issue: No ]
  • To assess in an exploratory fashion the predictive value of PML, phospho-TSC (S664), phospho-PRAS40, eIF4E, and FOXO expression with respect to response to everolimus. [ Time Frame: 3 years ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
Biomarker Trial of Everolimus in Patients With Advanced Renal Cell Carcinoma
A Phase II Biomarker Trial of Everolimus in Patients With Advanced Renal Cell Carcinoma

The purpose of this study is to determine if certain features of tumor specimens sampled prior to therapy can predict for the likelihood of responding to everolimus.

  • Participants will undergo a CT or ultrasound guided biopsy of an accessible tumor lesion before beginning the study medication.
  • Everolimus tablets will be taken orally once a day. Participants will undergo a physical exam and will be asked questions about their general health and specific questions about any problems they might be having. Photographs will be taken of the tumor to assess the response to treatment. This will be done by a CT or MRI scan. Blood tests will be performed every 4 weeks. In addition, blood for research purposes will be done on day 1 of every other cycle. A urine test will be done every 4 weeks.
Interventional
Phase 2
Allocation: Non-Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
  • Renal Cell Carcinoma
  • Renal Cancer
Drug: Everolimus
Tablet form taken orally once a day
Experimental: Treatment
This is a single-arm study. All patients will receive everolimus.
Intervention: Drug: Everolimus
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
40
August 2014
January 2014   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patients must have at least one site of disease which in the opinion of the investigator is safely accessible by CT guided biopsy or metastasectomy. Safely accessible metastatic disease will be defined to include those lesions which are palpable with no overlying viscera and are at least 2cm in size. Given the paucity of subcutaneous lesions in RCC, lesions which are felt to be safe to biopsy will also be allowed. These lesions include pleural-based tumors, peripheral liver lesions, kidney lesions and bone lesions with exophytic soft tissue component. As with palpable lesions, these other lesions should be at least 2cm in size with no overlying viscera.
  • At least one measurable site of disease, other than the biopsy site, according to RECIST criterial that has not been previously irradiated. Th the patient has had previous radiation to the marker lesion(s), there must be evidence of progression since the radiation
  • Metastatic renal carcinoma with histologic confirmation by the treating center of either primary or a metastatic lesion. Non-clear cell histologies will be allowed
  • 18 years of age or older
  • Minimum of four weeks since any major surgery, completion of radiation, or completion of all prior systemic anticancer therapy (adequately recovered from the acute toxicities of any prior therapy)
  • ECOG Performance status of 1 or less
  • Adequate bone marrow, liver and renal function as outlined in the protocol
  • Fasting serum cholesterol < 300mg/dL OR < 7.75 mmol/L AND fasting triglycerides < 2.5 x ULN
  • Life expectancy of greater than 6 months

Exclusion Criteria:

  • Prior treatment with any investigation drug within the preceding 4 weeks
  • Chronic treatment with systemic steroids or another immunosuppressive agent
  • Patients should not receive immunization with attenuated live vaccines within one week of study entry or during study period
  • Uncontrolled brain or leptomeningeal metastases, including patients who continue to require glucocorticoids for brain or leptomeningeal metastases. Treated brain metastases will be allowed. Treated brain metastases are defined as having no evidence of progression or hemorrhage after treatment and no ongoing requirement for dexamethasone, as ascertained by clinical examination and brain imaging (MRI or CT) during the screening period. Anticonvulsants (stable dose) are allowed. Treatment for brain metastases may include whole brain radiotherapy (WBRT), radiosurgery (RS: Gamma Knife, LINAC or equivalent) or a combination as deemed appropriate by the treating physician. Patients with CNS metastases treated by neurosurgical resection performed within 3 months prio to day 1 will be excluded.
  • Other malignancies within the past 3 years except for adequately treated carcinoma of the cervix or basal or squamous cell carcinomas of the skin
  • Patients who have any severe and/or uncontrolled medical conditions or other conditions that could affect their participation in the study
  • Uncontrolled diabetes mellitus as defined by a fasting serum > 1.5 x ULN
  • A known history of HIV seropositivity.
  • Impairment of gastrointestinal function or gastrointestinal disease that may significantly alter the absorption of everolimus
  • Patients with active, bleeding diathesis or on systemic anticoagulation. Aspirin is permitted.
  • Women who are pregnant or breast feeding, or women/men able to conceive and unwilling to practice an effective method of birth control.
  • Patients who have received prior treatment with an mTOR inhibitor.
  • Patients with known hypersensitivity to everolimus or other rapamycins or to its excipients.
  • History of noncompliance to medical regimens
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00827359
08-313
Yes
Daniel Cho, MD, Dana-Farber Cancer Institute
Beth Israel Deaconess Medical Center
  • Dana-Farber Cancer Institute
  • Duke University
  • Novartis
Principal Investigator: Daniel Cho, MD Beth Israel Deaconess Medical Center
Dana-Farber Cancer Institute
August 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP